Welcome to our dedicated page for Prestige Consmr Healthcare SEC filings (Ticker: PBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PBH SEC filings page on Stock Titan provides access to regulatory documents for Prestige Consumer Healthcare Inc., a New York Stock Exchange–listed consumer healthcare products company. These filings offer detailed information on the company’s financial condition, operations and material events related to its over-the-counter (OTC) healthcare brands.
Prestige’s periodic reports, such as its annual and quarterly filings, describe performance in its North American OTC Healthcare and International OTC Healthcare segments, along with discussions of revenues, operating income, net income, earnings per share, free cash flow and leverage. They also provide context on category trends across gastrointestinal, women’s health, cough and cold, eye and ear care and other consumer health areas, as well as the role of brands including Monistat®, Summer’s Eve®, Clear Eyes®, Dramamine®, Fleet®, Hydralyte® and others.
Current reports on Form 8-K, several of which are referenced in the provided data, disclose events such as the release of quarterly earnings, the use of investor presentations and the entry into a material definitive agreement to acquire Pillar5 Pharma Inc., a Canadian sterile ophthalmic manufacturer and current Clear Eyes® supplier. These filings outline key terms of the transaction, closing conditions and related risk considerations.
On Stock Titan, users can view Prestige Consumer Healthcare’s filings as they are made available through EDGAR and use AI-powered summaries to interpret complex sections. This includes understanding how management presents non-GAAP measures like adjusted net income and adjusted diluted earnings per share, as well as reviewing risk factor discussions, segment information and material agreements that shape the company’s OTC healthcare business.